GlassScriptPhysician profile
Edward Rydzak
NPI 1639157266
$4,674.36
in general payments reported to CMS, 2019-2025
30 companies · $877 in 2025
The $877 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $775 · 2020: $347 · 2021: $565 · 2022: $836 · 2023: $433 · 2024: $841 · 2025: $877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,151.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,234.22 | 2019-2025 | Rinvoq, Mavyret, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $483.33 | 2019-2025 | Xifaxan |
| Gilead Sciences, INC. | $355.78 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $183.82 | 2019-2025 | Entyvio |
| Celgene Corporation | $176.03 | 2021-2023 | Zeposia |
| Janssen Biotech, INC. | $170.40 | 2019-2025 | Stelara, Tremfya |
| Pfizer INC. | $144.70 | 2019-2025 | |
| Enterra Medical, INC. | $91.83 | 2025 | |
| Merck Sharp & Dohme LLC | $86.68 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $68.77 | 2019-2020 | |
| Ardelyx, INC. | $67.58 | 2022-2025 | Ibsrela |
| Endogastric Solutions, INC | $55.11 | 2022 | |
| Alnylam Pharmaceuticals INC. | $54.00 | 2023-2025 | Givlaari, Oxlumo |
| Allergan, INC. | $51.11 | 2019 | |
| Intercept Pharmaceuticals, INC. | $48.20 | 2019-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $47.07 | 2019 | |
| Redhill Biopharma INC. | $39.12 | 2021 | |
| Shionogi INC | $37.99 | 2019 | |
| Ferring Pharmaceuticals INC. | $36.72 | 2024-2025 | Clenpiq, Rebyota |
| Ucb, INC. | $35.23 | 2019 | |
| Nestle Healthcare Nutrition INC. | $33.42 | 2022-2023 | |
| Phathom Pharmaceuticals, INC. | $25.81 | 2024-2025 | Voquezna |
| Janssen Scientific Affairs, LLC | $23.74 | 2019 | |
| Organon LLC | $21.79 | 2024 | |
| Braintree Laboratories, INC. | $21.41 | 2019 | |
| Amgen INC. | $17.85 | 2023 | Avsola, Amjevita |
| Qol Medical, LLC | $17.16 | 2025 | Sucraid |
| Daiichi Sankyo INC. | $15.61 | 2020 | |
| Boston Scientific Corporation | $15.37 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $14.51 | 2025 | Iqirvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Rydzak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.